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Introduction. An in vivo determination of bile acid hepatobiliary transport efficiency can be of use in liver disease and
preclinical drug development. Given the increased interest in bile acid Positron Emission Tomography- (PET-) imaging, a further
understanding of the impact of 18-fluorine substitution on bile acid handling in vitro and in vivo can be of significance. Methods.
A number of bile acid analogues were conceived for nucleophilic substitution with [18F]fluoride: cholic acid analogues of which
the 3-, 7-, or 12-OH function is substituted with a fluorine atom (3𝛼-[18F]FCA; 7𝛽-[18F]FCA; 12𝛽-[18F]FCA); a glycocholic and
chenodeoxycholic acid analogue, substituted on the 3-position (3𝛽-[18F]FGCA and 3𝛽-[18F]FCDCA, resp.). Uptake by the bile acid
transporters NTCP andOATP1B1 was evaluated with competition assays in transfected CHO andHEK cell lines and efflux by BSEP
in membrane vesicles. PET-scans with the tracers were performed in wild-type mice (𝑛 = 3 per group): hepatobiliary transport
was monitored and compared to a reference tracer, namely, 3𝛽-[18F]FCA. Results. Compounds 3𝛼-[18F]FCA, 3𝛽-[18F]FGCA, and
3𝛽-[18F]FCDCA were synthesized in moderate radiochemical yields (4–10% n.d.c.) and high radiochemical purity (>99%); 7𝛽-
[18F]FCA and 12𝛽-[18F]FCA could not be synthesized and included further in this study. In vitro evaluation showed that 3𝛼-FCA,
3𝛽-FGCA, and 3𝛽-FCDCA all had a lowmicromolarKi-value forNTCP,OATP1B1, and BSEP. In vivo, 3𝛼-[18F]FCA, 3𝛽-[18F]FGCA,
and 3𝛽-[18F]FCDCA displayed hepatobiliary transport with varying efficiency. A slight yet significant difference in uptake and
efflux rate was noticed between the 3𝛼-[18F]FCA and 3𝛽-[18F]FCA epimers. Conjugation of 3𝛽-[18F]FCA with glycine had no
significant effect in vivo. Compound 3𝛽-[18F]FCDCA showed a significantly slower hepatic uptake and efflux towards gallbladder
and intestines. Conclusion. A set of 18F labeled bile acids was synthesized that are substrates of the bile acid transporters in vitro and
in vivo and can serve as PET-biomarkers for hepatobiliary transport of bile acids.
1. Introduction
Bile acids are steroid derivatives that are produced by the
hepatocytes of the liver and excreted in bile. These molecules
play an important role in micelle formation for lipid diges-
tion and uptake of fat-soluble vitamins in the intestines
[1]. The majority of bile acids (95%) is then reabsorbed
and transported back to the liver by the portal circulation.
Bile acid homeostasis in the liver is maintained by specific
bile acid transporters on the hepatocytes. Uptake at the
basolateral side relies predominantly on the Na+-dependent
Taurocholate Cotransporting Polypeptide (NTCP) and also
the Organic Anion Transporting Polypeptides (OATPs).
Once in the hepatocyte, excretion in the bile canaliculi
is mainly mediated by the Bile Salt Export Pump (BSEP)
[2].
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However, this highly efficient hepatobiliary transport of
bile acids can be disturbed by xenobiotics that inhibit the
aforementioned bile acid transporters or in certain liver
diseases such as primary biliary cirrhosis or progressive
familial intrahepatic cholestasis (PFIC) [3–5]. A toxic build-
up of bile acids in the hepatocytes, termed cholestasis, can
then present itself. Clinical features may consist of nausea,
abdominal pain, jaundice and pruritus [6]. An accurate
in vivo determination of bile acid transport efficiency can
therefore be valuable for detection or evaluation of liver
disease in both drug development and clinic.
To visualize physiological processes on a molecular level
in vivo, Positron Emission Tomography (PET) is the imaging
modality of choice. The possibility for close resemblance of
the PET-radiotracer and the endogenous substrate under
investigation gives this imaging technique an important asset
[7]. Recently, a number of studies with 11C or 18F labeled bile
acid PET-tracers have been published. Frisch et al. evaluated
11C labeled bile acids, conjugated with sarcosine or N-methyl
taurine in pigs [8, 9]. These tracers were able to visualize
hepatobiliary transport and can provide valuable information
in hepatobiliary diseases, although the short half-life of the
11C isotope limits their use. Several 18F labeled bile acids
were developed to overcome this issue. Jia et al. developed
a 18F labeled bile acid for studying Farnesoid X Receptor-
(FXR-) related diseases, using a click reaction of 1,3-dipolar
cycloaddition of terminal alkynes and organic azides [10].
However, this modification removes the terminal carboxylic
acid moiety that is critical for recognition by the bile acid
transporters [11]. Testa et al. improved this click chemistry
approach by retaining the carboxylic acid functional group
[12]. Nevertheless, for both 18F labeled compounds the intro-
duction of a long 1,2,3-triazole linked fluoroalkyl sidechain
on the carboxylic acid terminus encompasses a substantial
addition to the steroid structure. This might result in altered
hepatobiliary transport, compared to endogenous bile acids.
Because of the need for a 18F labeled bile acid with only
a minimal modification in molecular structure compared
to an endogenous bile acid, 3𝛽-[18F]fluorocholic acid (3𝛽-
[18F]FCA) was developed by our research group [13].The bile
acid structure for 3𝛽-[18F]FCA is cholic acid, of which the 3
alpha OH group was substituted for a 3-beta fluorine. This
tracer showed transport by NTCP, OATP, and BSEP in vitro
and could visualize hepatobiliary transport in vivo and drug-
induced alterations thereof.
Given the increased interest in bile acid PET-imaging,
a further understanding of the impact of fluorine-OH sub-
stitution on bile acid handling in vitro and in vivo can be
beneficial. Therefore, in this study a number of fluorinated
analogues of cholic, chenodeoxycholic, and glycocholic acid
were synthesized, evaluated, and compared in vitro and in
vivo in mice.
2. Materials and Methods
2.1. Radiosynthesis of the 18F-Labeled Bile Acids. The 18F-
isotope was introduced on the bile acid skeleton by a
nucleophilic substitution on a suitable mesylate, protected
precursor molecule of which the synthesis can be found in
Supplementary Data (available ). The conceived 18F labeled
bile acids are shown in Figure 1. The radiosynthesis was
performed as described earlier [13]. In short, [18F]fluoride
(1.3 GBq) was trapped on a Sep-Pak QMA-column (Waters,
Zellik, Belgium) that was preconditioned with 5mL 0.01M
K
2
CO
3
and 5mL ultrapure water. The activity was eluted
in a radiosynthesis vial with 1mL 9 : 1 AcN :H
2
O Cryptand-
2.2.2 (Acros Organics, Geel, Belgium) and K
2
CO
3
(20mg
and 2mg, resp.) solution. The solvents were removed by
evaporation under a gentle nitrogen flow at 100∘C. The
residue was dried further by adding and evaporating 2 ×
500 𝜇L AcN.
The precursor for radiosynthesis was dissolved in 200 𝜇L
anhydrous DMSO and added to the radiosynthesis vial. A
fixed amount (6.84𝜇mol; 3.4–4.4mg) of precursor for 3𝛼-
[18F]fluorocholic acid (3𝛼-[18F]FCA), 3𝛽-[18F]fluorocholic
acid (3𝛽-[18F]FCA), 7𝛽-[18F]fluorocholic acid (7𝛽-[18F]
FCA), 12𝛽-[18F]fluorocholic acid (12𝛽-[18F]FCA), 3𝛽-[18F]
fluoroglycocholic acid (3𝛽-[18F]FGCA), and 3𝛽-[18F]fluoro-
chenodeoxycholic acid (3𝛽-[18F]FCDCA) was used. The vial
was sealed, shaken, and heated for 20 minutes at 120∘C.
Afterwards, the vial was cooled and 100 𝜇L 5M NaOH
was added. The mixture was shaken and heated again at
120∘C for 10 minutes. After cooling and neutralization of
the basic reaction mixture, purification was performed by
a semipreparative HPLC-system (Grace Econosphere C18
10.0 × 250mm, 10 𝜇m; 6mL/min 10% AcN in H
2
O -> 100%
AcN in 20 minutes; radiodetection (Ludlum Measurements
Inc.)).The desired HPLC-fraction was collected, diluted with
ultrapure water to 50mL, and loaded on a Sep-Pak C18 Plus
short cartridge (preconditioned with 10mL EtOH and 10mL
ultrapure water). After washing with 10mL ultrapure water,
the 18F-labeled bile acid was eluted off the column with
1mL EtOH in a separate vial. This fraction was evaporated
under a gentleN
2
-flow andheating. Finally, 500𝜇Lphosphate
buffered saline was added to reformulate the tracer for in vivo
use.
The logD-value, stability (in formulation for use and
mouse serum), and identity of the tracer were assessed as
described earlier [13]. Radiochemical purity and percentage
18F-labeling of precursor were determined by radio-TLC (sil-
ica gel TLC; with 10% MeOH in CH
2
Cl
2
and 4 : 1 AcN :H
2
O,
resp.).
2.2. In Vitro Uptake Assays. Transport of the fluorinated
bile acids by NTCP and OATP1B1 was evaluated by their
inhibition of [3H]taurocholate ([3H]TC; Perkin Elmer)
and [3H]estradiol-17𝛽-glucuronide ([3H]EbG; Perkin Elmer)
uptake, respectively. Cholic acid (CA) was added to the test
compound panel as a reference. Chinese Hamster Ovary
(CHO) and Human Embryonic Kidney (HEK) cells express-
ing NTCP and OATP1B1, respectively (Solvo Biotechnolo-
gies), were used. Maintenance of these cell cultures was
described earlier [13].Ki-values of the different bile acidswere
calculated using the experimentally determined IC50-and
Km-parameters in the Cheng-Prusoff equation (GraphPad
Prism v3.00 Software) (see (1))
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Figure 1: 18F labeled bile acid analogues under investigation in the present study. Compounds 3𝛼-[18F]fluorocholic acid (3𝛼-[18F]FCA), 3𝛽-
[18F]fluorochenodeoxycholic acid (3𝛽-[18F]FCDCA), and 3𝛽-[18F]fluoroglycocholic acid (3𝛽-[18F]FGCA) on the upper row differ in bile acid
structure (cholic acid, chenodeoxycholic acid, and glycocholic acid) or 3 𝛼/𝛽 position of the radiolabel. The structures 12𝛽-[18F]fluorocholic
acid (12𝛽-[18F]FCA) and 7𝛽-[18F]fluorocholic acid (7𝛽-[18F]FCA) have the same cholic acid structure, but different position of the radiolabel
(7 or 12).
𝐾𝑖 =
IC50
1 + [𝑆] /𝐾𝑚
, (1)
where𝐾𝑖 refers to inhibition constant; IC50 refers to concen-
tration of fluorinated bile acid that causes a 50% decrease in
3H labeled substrate uptake; [𝑆] refers to concentration of 3H
labeled substrate; Km refers to Michaelis-Menten constant of
3H labeled substrate
Cells were seeded in 24-well plates at 400,000 cells/well.
The culturemediumwas aspirated after 24 hours and the cells
werewashed twice with 1mL 10mMHEPES-Hank’s Balanced
Salt Solution (HBSS; with Ca and Mg; 37∘C, pH 7). For Km-
determination, cells were incubated with 250 𝜇L of 0–150𝜇M
[3H]TC (NTCP) or [3H]EbG (OATP1B1) for 10 minutes at
37∘C. IC50-values were acquired by incubating the cells with
250 𝜇L 0–1000 𝜇M fluorinated bile acid and 1𝜇M [3H]TC
(NTCP) or [3H]EbG (OATP1B1) for 15 minutes at 37∘C. All
dosing solutions were formulated in the washing buffer and
dosingwas executed in triplicate.The incubationwas stopped
by placing the plates on ice and adding 1mL ice-cold 1%
BSA HBSS-solution. The supernatant was aspirated and the
cells were washed twice with 2mL ice-cold HBSS-solution.
NaOH(250 𝜇l, 0.1M)was added to lyse the cells and the plates
were shaken (15 minutes, 37∘C). Aliquots of this lysate were
subjected to liquid scintillation counting (TriCarb 2900 TR;
Perkin Elmer) and protein determination with a BCA-assay
(ThermoFisher Scientific).
2.3. InVitro EffluxAssays. Transport of the bile acids by BSEP
was evaluated by their inhibition of [3H]TC uptake in BSEP
membrane vesicles (Pharmtox). Cholic acid (CA) was added
to the test compound panel as a reference. Ki-values of the
different bile acids were calculated using the experimentally
determined IC50-and Km-parameters in the Cheng-Prusoff
equation (GraphPad Prism v3.00 Software) (see (1)). The
assay was performed in V-tip 96-well plates; each well con-
tained 3.75 𝜇g membrane vesicle, 10mMMgCl
2
, 10mM Tris,
4mM adenosine triphosphate (ATP), and 250mM sucrose.
A concentration range of 0–50 𝜇M [3H]TC was included for
the Km-determination. To determine the IC50s, 0–2500 𝜇M
of bile acid was used with 0.65𝜇M [3H]TC. All dosing was
performed in triplicate. The plates were suspended in a 37∘C
water bath 1 minute before the incubation. Incubation was
started by adding 10 𝜇L of the ATP solution or buffer solution
(negative control). Each well contained a final volume of
30 𝜇L and the plates were incubated for 10 minutes at
37∘C.
Transport was stopped by placing the plates on ice and
adding 150𝜇L ice-cold buffer solution. The contents of each
well were pipetted in a glass fiber filter plate (Multiscreen
HTS plates;MerckMillipore) andwashed 3 timeswith 200𝜇L
ice-cold buffer solution. Finally, 100 𝜇L 0.1M NaOH was
added: lysis of the vesicles took place for 10 minutes at room
temperature. An aliquot was used for liquid scintillation
counting.
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Table 1: Radiosynthesis characteristics of the different 18F labeled bile acids. The overall synthesis time was 100 minutes. n.d.c. RY: nondecay
corrected radiochemical yield. RP: radiochemical purity. Data are mean ± SD.
n.d.c. RY (%)
(n = 3)
18F labeling of precursor
(%)
(n = 3)
RP (%) LogD(n = 3)
3𝛼-[18F]FCA 10.56 ± 2.02 30.31 ± 1.28 >99 0.92 ± 0.17
3𝛽-[18F]FGCA 4.28 ± 0.39 11.51 ± 2.55 >99 0.011 ± 0.037
3𝛽-[18F]FCDCA 9.57 ± 1.51 28.27 ± 5.02 >99 1.42 ± 0.16
12𝛽-[18F]FCA <0.5 2.82 ± 1.14 NA NA
7𝛽-[18F]FCA <0.5 1.23 ± 0.26 NA NA
2.4. PET-Imaging Protocol. The in vivo transport character-
istics of the 18F labeled bile acids were evaluated in wild-
type FVB-mice (female, 5 w). The tracer described earlier
[13], 3𝛽-[18F]FCA, was also included as a reference standard.
Imaging was performed with a PET/CT (FLEX Triumph II
small animal PET/CT-scanner; axial field of view: 7.5 cm;
1.3mm spatial resolution; TriFoil Imaging). For each tracer,
three animals were used. The animals were housed and
handled in accordance with the European Ethics Committee
guidelines and the experiments were approved by the Animal
Experimental Ethical Committee of Ghent University (ECD
15/69).
Food andwater were provided ad libitum, but the animals
were fasted overnight before a PET/CT-scan. They were
anesthetized with 1.5 v : v% isoflurane in O
2
and placed on a
heated bed. To allow injection of the tracer, a polyethylene
intravenous line was inserted in the lateral tail vein and fixed.
After the animals were transferred to the scanner animal
bed, a 1 hour PET-scan was started and 9MBq tracer was
injected directly after starting the scan. Following this PET-
scan, 9MBq [18F]FDGwas injected and twentyminutes later,
a second PET-scan with a 20-minute acquisition time was
started.
All PET-scans were obtained in list-mode and were
iteratively reconstructed (50 iterations). The 1-hour scan was
reconstructed in the following frames: 8 × 15 s; 16 × 30 s;
10 × 60 s; 20 × 120 s. For presentation purposes, Maxi-
mum Intensity Projection PET/CT images were generated
in Amide software. The data were analyzed using Pmod
software v3.405 (PMOD Technologies): Regions Of Interest
(ROIs) were drawn manually over the liver, gallbladder, and
intestines. On the static [18F]FDG scan, the left ventricle was
delineated and this ROI was pasted on the dynamic scan to
obtain an image-derived arterial blood concentration. The
uptake of radioactivity in liver, gallbladder, and intestines was
expressed as a percentage of the injected dose (% ID) and
normalized for the weight of a 20 g mouse.The % ID in these
organs was monitored in function of time to obtain time-
activity curves (TACs). Biliary clearance of the tracers was
determined with equation 2 from Ghibellini et al. [14]
Biliary clearance
=
cumulative amount of tracer in gallbladder&intestines
AUC blood concentration
0→60min
.
(2)
The Area Under the Curve (AUC), % ID, and time-to-
peak values of the TACs were determined in GraphPad Prism
v3.00 Software. The obtained parameters of the different 18F
labeled bile acids were compared to 3𝛽-[18F]FCA-values in
SPSS Statistics 23 Software. Differences between two groups
were analyzed with the nonparametric Mann–Whitney U
test. A 𝑝 value ≤ 0.05 was considered significant.
3. Results
3.1. Radiosynthesis of the 18F-Labeled Bile Acids. Differences
in radiolabeling yield of the precursors for radiosynthesis
with [18F]fluoride were observed (Table 1). The precursors
for 3𝛼-[18F]FCA and 3𝛽-[18F]FCDCA had approximately
the same labeling yield (30%) and nondecay corrected yield
(10%). The precursor for 3𝛽-[18F]FGCA was only labeled for
11.51 ± 2.55%, which also resulted in a lower total yield of
4.28±0.39%.The tracers 3𝛼-[18F]FCA, 3𝛽-[18F]FCDCA, and
3𝛽-[18F]FGCAwere found to be stable in its formulation and
in mouse serum. Both the precursors for 12𝛽-[18F]FCA and
7𝛽-[18F]FCA provided minimal radiolabeling: generating a
significant amount of completed product proved troublesome
for these two products. Furthermore, the 7𝛽FCA reference
compound could not be synthesized. The LogD values of the
18F labeled bile acids are displayed in Table 1.
3.2. In Vitro Uptake Assays. A Michaelis-Menten curve was
made for [3H]TC and [3H]EbG for the CHO-NTCP and
HEK-OATP1B1 cells, respectively (Figure 2). For the CHO-
NTCP cells, the Km of [3H]TC was 15.27 ± 2.46 𝜇M and
the Vmax 200.4 ± 9.77 pmol/min⋅mg protein. For the HEK-
OATP1B1 cells, the Km of [3H]EbG was 11.72 ± 1.59 𝜇M and
the Vmax 146.4 ± 5.52 pmol/min⋅mg protein.
Cholic acid and the fluorinated bile acid analogues
caused a dose-dependent decrease in the uptake of [3H]TC
and [3H]EbG for NTCP and OATP1B1. A sigmoidal dose-
response curve was fitted on the acquired data points to
determine the IC50 and calculate the Ki-value (Figure 3 and
Table 2).
3.3. In Vitro Efflux Assays. A Michaelis-Menten curve of
[3H]TCwasmade for BSEP (Figure 2).TheKmof [3H]TCwas
3.89 𝜇M ± 1.44 𝜇M and the Vmax 34.97 ± 3.57 pmol/min⋅mg
protein. Cholic acid and the fluorinated bile acid analogues
caused a dose-dependent decrease in the uptake of [3H]TC
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Figure 2: Graphs of the concentration dependent uptake of [3H]TC in CHO-NTCP cells and BSEP membrane vesicles. [3H]EbG was used
in HEK-OATP1B1 cells. All data are mean ± SD (𝑛 = 3).
Table 2: Calculated Ki-values of the bile acid analogues for NTCP, OATP1B1, and BSEP. Data are mean ± SD (n = 3). ∗3𝛽FCA IC50-values
were extracted from literature [13] and used to calculate the Ki-values.
Ki for NTCP (𝜇M) Ki for OATP1B1 (𝜇M) Ki for BSEP (𝜇M)
CA 12.96 ± 4.26 42.70 ± 0.16 95.46 ± 33.97
3𝛼FCA 2.53 ± 0.76 5.22 ± 0.56 198.93 ± 39.47
3𝛽FCA∗ 6.18 ± 0.59 9.67 ± 0.83 216.30 ± 52.99
3𝛽FGCA 1.09 ± 0.34 4.24 ± 0.16 87.38 ± 14.61
3𝛽FCDCA 0.91 ± 0.02 0.64 ± 0.07 48.24 ± 3.94
12𝛽FCA 30.08 ± 9.40 4.56 ± 0.25 367.02 ± 38.11
in the BSEP membrane vesicles. A sigmoidal dose-response
curve was fitted on the acquired data points to determine the
IC50 and calculate the Ki-value (Figure 3 and Table 2).
3.4. In Vivo Evaluation of the 18F-Labeled Bile Acids. The
18F labeled bile acids 3𝛼-[18F]FCA, 3𝛽-[18F]FCA, 3𝛽-[18F]
FGCA, and 3𝛽-[18F]FCDCA were evaluated in wild-type
mice. Because of their negligible radiochemical yield, 7𝛽-
[18F]FCA and 12𝛽-[18F]FCA could not be included. Com-
pounds 3𝛽-[18F]FCA, 3𝛼-[18F]FCA, 3𝛽-[18F]FGCA, and 3𝛽-
[18F]FCDCA showed exclusive hepatic uptake after intra-
venous injection. The hepatic uptake of reference tracer 3𝛽-
[18F]FCA was significantly slower than 3𝛼-[18F]FCA (5.33 ±
0.24 versus 3.33 ± 0.62minutes), but significantly faster than
3𝛽-[18F]FCDCA (5.33 ± 0.24 versus 10.17 ± 0.62 minutes).
There was no difference in the time-to-peak of the liver TAC
of 3𝛽-[18F]FCA and 3𝛽-[18F]FGCA. Once in the liver, the
tracers were excreted in gallbladder and intestines. Almost
all of the injected activity (approx. 80%) of 3𝛼-[18F]FCA,
3𝛽-[18F]FCA, and 3𝛽-[18F]FGCA was found in gallbladder
and intestines after 1 hour. Due to slower excretion of 3𝛽-
[18F]FCDCA from the liver, only 60% of the injected dose
was found in gallbladder and intestines after 1 hour. Of the
four tracers, only the biliary clearance of 3𝛽-[18F]FCDCA
(0.18 ± 0.04mL/min) was significantly different compared
to 3𝛽-[18F]FCA (0.46 ± 0.08mL/min). No radioactivity was
observed in other organs for all tracers under investigation.
Time-activity curves of the 18F labeled bile acids were
generated and the relevant parameters were extracted from
these graphs (Figure 4 and Table 3). Representative PET/CT
images of 3𝛽-[18F]FGCA and 3𝛽-[18F]FCDCA are displayed
in Figure 5.
4. Discussion
Cholestasis, a toxic accumulation of bile acids in the liver or
blood, may occur in certain liver diseases or can be triggered
as a result of a xenobiotic interfering with the hepatobiliary
transport of bile acids [15]. It is therefore important to have an
adequate tool to evaluate the efficiency of bile acid transport
in vivo for clinical use or in drug development.
To that end, PET-imaging of hepatobiliary transport with
radiolabeled bile acids is gaining importance. A number of
studies have been published in which bile acids were labeled
with either 11C or 18F on different bile acid structures [8–
10, 12]. Our research group developed 3𝛽-[18F]fluorocholic
acid (3𝛽-[18F]FCA), a cholic acid derivative of which the
3𝛼-OH function is substituted for a 3𝛽-fluorine atom. This
minimal modification of the endogenous molecule allowed
visualization and quantification of bile acid hepatobiliary
transport and drug-induced alterations thereof. Seeing the
promising results with 3𝛽-[18F]FCA and the increased inter-
est in hepatobiliary imaging with PET, a further exploration
of fluorinated bile acid transport characteristics was per-
formed in this study. A number of fluorinated analogues
were conceived: cholic acid derivatives of which the 3, 7,
and 12 OH functions were replaced with a fluorine atom, a
3𝛽-fluorine labeled chenodeoxycholic acid, and 3𝛽-fluorine
labeled glycocholic acid. These compounds were evaluated
on their radiosynthesis characteristics, in vitro and in vivo
hepatobiliary transport in wild-type mice.
Of the conceived 18F labeled bile acids, only 3𝛼-[18F]FCA,
3𝛽-[18F]FGCA, and 3𝛽-[18F]FCDCA could be obtained in
a suitable radiochemical yield. The 18F labeling yield of the
precursor molecules for 3𝛼-[18F]FCA and 3𝛽-[18F]FCDCA
was comparable to that of 3𝛽-[18F]FCA described earlier
6 Contrast Media & Molecular Imaging
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Figure 3: Graphs of the concentration dependent decrease in uptake of tritium labeled substrate ([3H]TC for NTCP and BSEP; [3H]EbG for
OATP1B1). IC50s of the compounds were determined by GraphPad, and their respective Ki-values can be found in Table 2. All data are mean
± SD (𝑛 = 3).
(approx. 30%) [13]. Labeling of the 3𝛽-[18F]FGCA precursor
was only 11.51±2.55%.This reduced yield could be attributed
to the presence of amore polar amide group on the precursor,
which can reduce the [18F]fluoride nucleophilic substitution
efficiency. LogD values of the three tracers mentioned above
were determined and were in line with literature LogD values
of cholic acid, chenodeoxycholic acid, and glycocholic acid
[16].
The mesylate precursors for 12𝛽-[18F]FCA and 7𝛽-[18F]
FCA could not be substituted efficiently with [18F]fluoride
and could therefore not be included in the in vivo evaluation.
The 7𝛼- and 12𝛼- mesyl groups on cholic acid are positioned
axially on steroid rings B and C, respectively. Coupled to the
presence of neighboring hydrogen atoms that can be removed
by a base, these positions are more prone to elimination than
substitution with [18F]fluoride. This observation was also
made in the attempted synthesis of the 12𝛽-[18F]FCA and 7𝛽-
[18F]FCA reference compounds. The 7𝛽FCA synthesis with
DAST resulted exclusively in the formation of elimination
product. However, it was possible to synthetize the 12𝛽-FCA
reference compound in low yield, as there are less protons
available for elimination by a base due to the 19-methyl group
Contrast Media & Molecular Imaging 7
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Figure 4: Time-activity curves (TACs) of 3𝛼-[18F]FCA, 3𝛽-[18F]FCA, 3𝛽-[18F]FGCA, and 3𝛽-[18F]FCDCA in liver (red curve) and
gallbladder and intestines (GBI; green curve) of wild-typemice. Uptake of the tracers was expressed as% injected dose (% ID) and normalized
for a 20 g mouse. Data are mean ± SD (𝑛 = 3 per group).
present near the 12𝛼-mesyl-group. In vitro data for 12𝛽-FCA
could be acquired, but no in vivo PET-imaging was possible.
Ki-values of CA, 3𝛼FCA, 3𝛽FGCA, 3𝛽FCDCA, and
12𝛽FCA for the bile acid transporters NTCP, OATP1B1,
and BSEP were determined as an affinity measure. It was
demonstrated that these compounds caused a concentration
dependent decrease in uptake of the tritium labeled model
substrates of NTCP, OATP1B1, and BSEP. The substitution of
the 3-OH function by a more lipophilic fluorine atom on the
3𝛼- and 3𝛽-position of CA causes an increase in affinity for
NTCP andOATP1B1, yet gives rise to a decrease in affinity for
theBSEP-transporter compared toCA.Althoughboth 3-FCA
epimers are a substrate for the bile acid transporters, 3𝛼-FCA
displays a slightly higher affinity than 3𝛽-FCA for NTCP and
OATP1B1 (2.53 ± 0.76 𝜇M and 5.22 ± 0.56 𝜇M, resp., versus
6.18 ± 0.59 and 9.67 ± 0.83 𝜇M, resp.). The affinity for BSEP
does not change. This difference in affinity for 3 𝛼/𝛽 cholic
acid epimers of bile acid transporters was already uncovered
in cell lines that express the Apical Sodium-dependent Bile
acid Transporter (ASBT; responsible for basolateral uptake
of bile acids in the enterocytes). It was found that 3𝛽-
OH-bile acids have a lower affinity than 3𝛼OH-bile acids
for ASBT [17]. In the present study, the hepatic basolateral
uptake transporters NTCP and OATP1B1 also reveal a slight
preference in affinity for the 3𝛼-fluorocholic acid epimer.
Compound 3𝛽-FGCA, 3𝛽-cholic acid conjugated with the
amino acid glycine, showed an increase in affinity for all bile
acid transporters under investigation. This is in line with
literature data: conjugated bile acids have a higher affinity for
NTCP,OATP, andBSEP than nonconjugated bile acids [2, 18].
The PET-scans with 3𝛽-[18F]FCA, 3𝛼-[18F]FCA, 3𝛽-
[18F]FGCA, and 3𝛽-[18F]FCDCA showed hepatobiliary
transport after intravenous injection in healthy wild-type
FVB-mice. The former three tracers displayed fairly similar
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Table 3: Metrics of the 18F labeled bile acids time-activity curves. The values are expressed as mean ± SD (n = 3). Significant differences
compared to the 3𝛽-[18F]FCA values are marked with ∗. A 𝑝 value ≤ 0.05 was considered significant. GBI = gallbladder and intestines; AB =
arterial blood.
3𝛽-[18F]FCA 3𝛼-[18F]FCA 3𝛽-[18F]FGCA 3𝛽-[18F]FCDCA
AUC liver (% ID⋅min) 1785 ± 194 1065 ± 171∗ 1907 ± 58 2449 ± 111∗
Max% ID liver (%) 63.80 ± 2.61 58.58 ± 3.19 63.58 ± 1.84 51.01 ± 3.94∗
Time-to-peak liver (min) 5.33 ± 0.24 3.33 ± 0.62∗ 5.17 ± 0.62 10.17 ± 0.62∗
AUC GBI (% ID⋅min) 3499 ± 340 4184 ± 109∗ 3021 ± 276 2515 ± 189∗
Max% ID GBI (%) 83.44 ± 9.27 88.70 ± 2.38 75.32 ± 6.30 60.93 ± 7.29∗
AUC AB concentration (MBq⋅min/mL) 13003 ± 1032 14007 ± 2150 10192 ± 1404 28437 ± 4380∗
Biliary clearance (mL/min) 0.46 ± 0.08 0.49 ± 0.10 0.47 ± 0.07 0.18 ± 0.04∗
3–20min 20–60min
3-[18F]FGCA
3-[18F]FCDCA
Figure 5: RepresentativeMaximum Intensity Projection PET/CT of
9MBq 3𝛽-[18F]FGCA and 3𝛽-[18F]FCDCA in a wild-type mouse
(slice thickness: 12mm). After intravenous injection, both tracers
showed exclusive uptake in the liver (3–20 minutes).The 18F labeled
bile acids were then excreted in gallbladder and intestines. Biliary
excretion of 3𝛽-[18F]FCDCA is visually slower than 3𝛽-[18F]FGCA
(20–60 minutes after injection).
TAC-curves, whereas 3𝛽-[18F]FCDCAhad themost aberrant
curves. Compared to 3𝛽-[18F]FCA, there is a significantly
slower liver uptake from the blood compartment: both the
time-to-peak of the liver TAC and the AUC of tracer in arte-
rial blood increased approximately twofold. Furthermore,
a significant drop in excretion towards gallbladder and
intestines was observed. This slower hepatobiliary clearance
of 3𝛽-[18F]FCDCA in vivo, although coupled with the in vitro
observation that this fluorinated bile acid has a very high
affinity for the bile acid transporters, implies that 3𝛽FCDCA
acts as slow substrate for the bile acid transporters in vivo.
Because 3𝛽-[18F]FCDCA already shows slower hepatobiliary
transport in healthy wild-type mice, this tracer is less suited
to detect possible alterations of bile acids transport by
pharmacological interference or in liver disease.
Considering the 3𝛼/𝛽-[18F]FCA epimers, it was found
that 3𝛼-[18F]FCA shows a slight, yet significant decrease in
time-to-peak of the liver TAC and excretion to gallbladder
and intestines proceeded faster. This is reflected in a decrease
of the liver TAC AUC-value and modest increase in AUC
of the gallbladder and intestines TAC compared to 3𝛽-
[18F]FCA. These results illustrate that there is not only an
observable difference in affinity of the 3𝛼/𝛽 FCA epimers
for bile acid transporters in vitro, but also in hepatobiliary
transport in vivo.There is a slight preference for 3𝛼-[18F]FCA
compared to 3𝛽-[18F]FCA, probably because the fluorine
atom is in the same 3𝛼-configuration as the 3𝛼-OH on the
endogenous cholic acid molecule.
Conjugation of 3𝛽-[18F]FCA with glycine did not have
a significant impact on its in vivo hepatobiliary transport,
although the affinity of 3𝛽FGCA for NTCP, OATP1B1, and
BSEP rises compared to 3𝛽FCA in vitro. This means that
glycine conjugation of a bile acid is not a prerequisite for faster
or more efficient hepatobiliary transport in mice.Themajor-
ity of the murine bile acid spectrum is however composed
of taurine conjugated bile acids [19]. The observed identical
transport efficiency of 3𝛽-[18F]FCA and its glycine conjugate
3𝛽-[18F]FGCA could be different if taurine conjugation were
explored.
Two out of three newly developed tracers (3𝛼-[18F]FCA
and 3𝛽-[18F]FGCA) display fast and efficient hepatobiliary
transport and can therefore be employed as biomarker for
bile acid transport in vivo. Given the observed discrep-
ancy between in vitro affinity and the in vivo hepatobiliary
transport of some bile acid transporter substrates (such as
3𝛽FGCA and 3𝛽FCDCA), it is still important to determine
the in vivo kinetics of a bile acid transporter substrate and not
to rely on in vitro results alone to assess potentially disturbed
hepatobiliary transport of bile acids.
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5. Conclusion
A set of 18F labeled bile acids were synthesized in a mod-
erate radiochemical yield: 3𝛼-[18F]FCA, 3𝛽-[18F]FGCA, and
3𝛽-[18F]FCDCA. All tracers were in vitro substrates of
the bile acid transporters NTCP, OATP1B1, and BSEP and
showed hepatobiliary transport in vivo. It was found that 3𝛼-
[18F]FCA shows slightly faster hepatobiliary transport than
its epimer, 3𝛽-[18F]FCA. Conjugation of 3𝛽-[18F]FCA with
glycine is not a prerequisite for faster transport. The 18F
labeled bile acids 3𝛼-[18F]FCA and 3𝛽-[18F]FGCA can be
applied as biomarker for in vivo PET monitoring of hepato-
biliary transport of bile acids.The 18F-chenodeoxycholic acid
derivative, however, 3𝛽-[18F]FCDCA, suffers from slower
hepatobiliary transport than its cholic acid counterpart and
is hence less suited for monitoring possible disturbances of
bile acid transport in vivo.
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